Oramed Pharmaceuticals Inc.
ORMP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $93,923 | $88,230 | $96,605 |
| - Cash | $52,179 | $15,797 | $74,516 | $54,420 |
| + Debt | $589 | $912 | $301 | $372 |
| Enterprise Value | – | $79,038 | $14,015 | $42,557 |
| Revenue | $0 | $0 | $2,000 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | -$31 | -$30 | $13 | -$31 |
| % Margin | – | – | 0.7% | – |
| EBITDA | $59,482 | $13,164 | -$4,470 | -$9,752 |
| % Margin | – | – | -223.5% | – |
| Net Income | $48,395 | $13,288 | -$7,642 | -$10,189 |
| % Margin | – | – | -382.1% | – |
| EPS Diluted | 1.13 | 0.31 | -0.19 | -0.26 |
| % Growth | 264.5% | 263.2% | 26.9% | – |
| Operating Cash Flow | -$1,987 | -$3,569 | -$3,519 | -$1,935 |
| Capital Expenditures | -$0 | -$4 | -$3 | -$11 |
| Free Cash Flow | -$1,987 | -$3,573 | -$3,522 | -$1,946 |